|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Power DG, Kelsen DP and Shah MA: Advanced
gastric cancer - slow but steady progress. Cancer Treat Rev.
36:384–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marin JJ, Al-Abdulla R, Lozano E, Briz O,
Bujanda L, Banales JM and Macias RI: Mechanisms of resistance to
chemotherapy in gastric cancer. Anticancer Agents Med Chem. Aug
3–2015.(Epub ahead of print). PubMed/NCBI
|
|
4
|
Kim SM and Park SH: Chemotherapy beyond
second-line in advanced gastric cancer. World J Gastroenterol.
21:8811–8816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Covell LL and Ganti AK: Treatment of
advanced thyroid cancer: Role of molecularly targeted therapies.
Target Oncol. 10:311–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kito Y and Yamazaki K: Targeted therapies
for metastatic colorectal cancer. Nihon Rinsho. 73:1384–1390.
2015.(In Japanese). PubMed/NCBI
|
|
7
|
Wahler J and Suh N: Targeting HER2
Positive breast cancer with chemopreventive agents. Curr Pharmacol
Rep. 1:324–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP,
Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, et al: Phase II study of
trastuzumab in combination with S-1 and cisplatin in the first-line
treatment of human epidermal growth factor receptor HER2-positive
advanced gastric cancer. Cancer Chemother Pharmacol. 76:397–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang
C, Chen Z, Li W, Shen H and Ying S: Effectiveness and safety of
poly (ADP-ribose) polymerase inhibitors in cancer therapy: A
systematic review and meta-analysis. Oncotarget. Sep 22–2015.(Epub
ahead of print).
|
|
10
|
Abu-Khalaf MM, Baumgart MA, Gettinger SN,
Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K,
Zelterman D, et al: Phase 1b study of the mammalian target of
rapamycin inhibitor sirolimus in combination with nanoparticle
albumin-bound paclitaxel in patients with advanced solid tumors.
Cancer. 121:1817–1826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brana I, Berger R, Golan T, Haluska P,
Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani
P, et al: A parallel-arm phase I trial of the humanised anti-IGF-1R
antibody dalotuzumab in combination with the AKT inhibitor MK-2206,
the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752,
in patients with advanced solid tumours. Br J Cancer.
111:1932–1944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB, et al: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi J, Yao D, Liu W, Wang N, Lv H, Zhang
G, Ji M, Xu L, He N, Shi B, et al: Highly frequent PIK3CA
amplification is associated with poor prognosis in gastric cancer.
BMC Cancer. 12:502012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsuoka T and Yashiro M: The Role of
PI3K/Akt/mTOR Signaling in Gastric Carcinoma. Cancers (Basel).
6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parsons CM, Muilenburg D, Bowles TL,
Virudachalam S and Bold RJ: The role of Akt activation in the
response to chemotherapy in pancreatic cancer. Anticancer Res.
30:3279–3289. 2010.PubMed/NCBI
|
|
18
|
Lin YH, Chen BY, Lai WT, Wu SF, Guh JH,
Cheng AL and Hsu LC: The Akt inhibitor MK-2206 enhances the
cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer
cells. Naunyn Schmiedebergs Arch Pharmacol. 388:19–31. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duan L, Perez RE, Hansen M, Gitelis S and
Maki CG: Increasing cisplatin sensitivity by schedule-dependent
inhibition of AKT and Chk1. Cancer Biol Ther. 15:1600–1612. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Riquelme I, Saavedra K, Espinoza JA, Weber
H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC and Bizama C:
Molecular classification of gastric cancer: Towards a
pathway-driven targeted therapy. Oncotarget. 6:24750–24779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Benada J and Macurek L: Targeting the
checkpoint to kill cancer cells. Biomolecules. 5:1912–1937. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nicolini A, Ferrari P, Kotlarova L, Rossi
G and Biava PM: The PI3K-AKt-mTOR pathway and new tools to prevent
acquired hormone resistance in breast cancer. Curr Pharm
Biotechnol. 16:804–815. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pandey R and Kapur R: Targeting
phosphatidylinositol-3-kinase pathway for the treatment of
Philadelphia-negative myeloproliferative neoplasms. Mol Cancer.
14:1182015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang L, Wu J, Ling MT, Zhao L and Zhao
KN: The role of the PI3K/Akt/mTOR signalling pathway in human
cancers induced by infection with human papillomaviruses. Mol
Cancer. 14:872015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Almhanna K, Cubitt CL, Zhang S, Kazim S,
Husain K, Sullivan D, Sebti S and Malafa M: MK-2206, an Akt
inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric
cancer cell lines. Cancer Biol Ther. 14:932–936. 2013. View Article : Google Scholar : PubMed/NCBI
|
